ArticleAntimicrobial agents and chemotherapy2026
A multi-center, open-label, two-part study to investigate the effect of renal function and hemodialysis on the pharmacokinetics of the novel β-lactamase inhibitor nacubactam.
Jun Morita et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.